Related Experiment Video
Updated: May 23, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Topical JAK inhibitor for refractory skin inflammation in STAT1 GOF
Valentina Guarnieri1,2, Tiphaine Arlabosse1, Claire Booth1,3
1Department of Immunology and Gene Therapy, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Abstract:
Topical ruxolitinib led to marked improvement in refractory facial dermatitis in a 10-year-old patient with STAT1 gain-of-function. These findings support localized inhibition of dysregulated JAK-STAT signaling as a well-tolerated and effective treatment for cutaneous manifestations of STAT1 gain-of-function disease.
Related Concept Videos
The JAK-STAT Signaling Pathway
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Staphylococcal Skin Infections
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
